

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 August 2025 (14.08.2025)



(10) International Publication Number
WO 2025/166413 A1

(51) International Patent Classification:

A61K 38/26 (2006.01) *A61K 31/7034* (2006.01)
A61K 9/00 (2006.01) *A61P 3/10* (2006.01)
A61K 9/70 (2006.01)

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/AU2025/050085

(22) International Filing Date:

05 February 2025 (05.02.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2024900259 05 February 2024 (05.02.2024) AU

(71) Applicants: **IX BIOPHARMA LIMITED** [AU/AU]; 24 Augusta Street, Willetton, Western Australia 6155 (AU). **IX BIOPHARMA LTD** [SG/SG]; 1 Kim Seng Promenade, Great World City Office Tower, East Tower, #14-01, Singapore 237994 (SG).

(72) Inventors: **LIM, Chin Beng Stephen**; 1 Kim Seng Promenade, Great World City Office Tower, East Tower, #14-01, Singapore 237994 (SG). **COOK, Iain Bruce**; 1 Kim Seng Promenade, Great World City Office Tower, East Tower, #14-01, Singapore 237994 (SG). **LEE, Yip Hang Eddy**; 1 Kim Seng Promenade, Great World City Office Tower, East Tower, #14-01, Singapore 237994 (SG). **KRISHNARAJAH, Janakan**; 1 Kim Seng Promenade, Great World City Office Tower, East Tower, #14-01, Singapore 237994 (SG).

(74) Agent: **WRAYS PTY LTD**; Level 7, 863 Hay Street, Perth, Western Australia 6000 (AU).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

WO 2025/166413 A1

(54) Title: COMPOSITIONS AND METHODS FOR DELIVERING GLP-1 AGONISTS (METABOLIX)

(57) Abstract: A composition comprising a glucagon-like peptide 1 (GLP-1) agonist for sublingual or buccal administration, wherein the composition comprises one or more agents selected from the group consisting of: sodium glycodeoxycholate; sodium deoxycholate; carboxymethyl cellulose; sodium alginate; SNAC (salcaprozate sodium); a non-ionic ester alkoxylate (or alkanolic acid ester alkoxylate); and soy lecithin.